Ipsen is bolstering its portfolio in ultra rare diseases by buying Clementia Pharmaceuticals Inc. of Canada and in so doing reinforcing its strategy of buying first-in-class or best-in-class assets in mid-to-late stage development that offer promising commercial prospects, according to the French pharma's chief commercial officer.
Ipsen is paying $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?